The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
Abstract Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. However, the relationship between the PLR and prognosis in myeloma patients...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-84343-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594665610674176 |
|---|---|
| author | Quane Zhang Yifan Wang Wenting Shi Yue Chen Zhengmei He Liang Yu Chunling Wang |
| author_facet | Quane Zhang Yifan Wang Wenting Shi Yue Chen Zhengmei He Liang Yu Chunling Wang |
| author_sort | Quane Zhang |
| collection | DOAJ |
| description | Abstract Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. However, the relationship between the PLR and prognosis in myeloma patients has not been clearly demonstrated. In our study, we included 122 newly diagnosed MM patients who were treated with bortezomib-based chemotherapy. These patients were divided into low-PLR and high-PLR groups based on their initial PLR values. We compared the clinical characteristics between the two groups and utilized restricted cubic splines (RCSs) in the regression model to estimate the nonlinear relationship between the initial PLR and overall survival (OS) in MM patients. The results showed that patients in the low-PLR group had significantly worse OS (P = 0.00031) and progression-free survival (PFS) (P < 0.0001) compared to those in the high-PLR group. Furthermore, within the higher-risk MM group, a low PLR was also associated with worse OS (P = 0.0037) and PFS (P = 0.0048). Therefore, a low PLR was identified as an independent predictor of poor OS in MM patients. The RCS curves further confirmed a significant nonlinear relationship between the PLR and OS in patients with MM. The PLR may serve as a significant independent prognostic indicator for MM patients undergoing bortezomib-based chemotherapy, and there exists a crucial nonlinear relationship between the PLR and OS in these patients. |
| format | Article |
| id | doaj-art-0064c0ea686f45c9aae40d63dda9c67b |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-0064c0ea686f45c9aae40d63dda9c67b2025-01-19T12:24:11ZengNature PortfolioScientific Reports2045-23222025-01-011511910.1038/s41598-024-84343-xThe prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimenQuane Zhang0Yifan Wang1Wenting Shi2Yue Chen3Zhengmei He4Liang Yu5Chunling Wang6Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical UniversityDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical UniversityDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical UniversityDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical UniversityDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical UniversityDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical UniversityDepartment of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical UniversityAbstract Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. However, the relationship between the PLR and prognosis in myeloma patients has not been clearly demonstrated. In our study, we included 122 newly diagnosed MM patients who were treated with bortezomib-based chemotherapy. These patients were divided into low-PLR and high-PLR groups based on their initial PLR values. We compared the clinical characteristics between the two groups and utilized restricted cubic splines (RCSs) in the regression model to estimate the nonlinear relationship between the initial PLR and overall survival (OS) in MM patients. The results showed that patients in the low-PLR group had significantly worse OS (P = 0.00031) and progression-free survival (PFS) (P < 0.0001) compared to those in the high-PLR group. Furthermore, within the higher-risk MM group, a low PLR was also associated with worse OS (P = 0.0037) and PFS (P = 0.0048). Therefore, a low PLR was identified as an independent predictor of poor OS in MM patients. The RCS curves further confirmed a significant nonlinear relationship between the PLR and OS in patients with MM. The PLR may serve as a significant independent prognostic indicator for MM patients undergoing bortezomib-based chemotherapy, and there exists a crucial nonlinear relationship between the PLR and OS in these patients.https://doi.org/10.1038/s41598-024-84343-xPlatelet-to-lymphocyte ratioMultiple myelomaPrognostic factorsBortezomib-based chemotherapyRestricted cubic splines |
| spellingShingle | Quane Zhang Yifan Wang Wenting Shi Yue Chen Zhengmei He Liang Yu Chunling Wang The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen Scientific Reports Platelet-to-lymphocyte ratio Multiple myeloma Prognostic factors Bortezomib-based chemotherapy Restricted cubic splines |
| title | The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen |
| title_full | The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen |
| title_fullStr | The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen |
| title_full_unstemmed | The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen |
| title_short | The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen |
| title_sort | prognostic value of the platelet to lymphocyte ratio in multiple myeloma patients treated with a bortezomib based regimen |
| topic | Platelet-to-lymphocyte ratio Multiple myeloma Prognostic factors Bortezomib-based chemotherapy Restricted cubic splines |
| url | https://doi.org/10.1038/s41598-024-84343-x |
| work_keys_str_mv | AT quanezhang theprognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT yifanwang theprognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT wentingshi theprognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT yuechen theprognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT zhengmeihe theprognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT liangyu theprognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT chunlingwang theprognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT quanezhang prognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT yifanwang prognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT wentingshi prognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT yuechen prognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT zhengmeihe prognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT liangyu prognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen AT chunlingwang prognosticvalueoftheplatelettolymphocyteratioinmultiplemyelomapatientstreatedwithabortezomibbasedregimen |